AcelRx Pharmaceuticals investor relations material

Listen to the latest call from AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA™ (sufentanil sublingual tablet, 30 mcg) which has completed Phase 3 trials. The Company believes that DSUVIA is a potential first-in-class non-invasive treatment option that can deliver rapid relief to patients suffering from moderate to severe acute pain.

  • Ticker

  • Country


Dig deeper into the AcelRx Pharmaceuticals fundamentals on Quartr.